Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 10/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211475 | 0.88 | ENPP1 (0.39) | ENPP1ADORA2A | |
| SCHEMBL31211252 | 0.87 | PTPN11 (0.39) | USP30 | |
| SCHEMBL25105311 | 0.86 | ENPP1 (0.37) | ENPP1ADORA2A | |
| SCHEMBL25105375 | 0.85 | USP30 (0.39) | ENPP1SUV39H2PARP1USP30CKS1B | |
| SCHEMBL31210572 | 0.84 | WDR5 (0.34) | ENPP1USP30ADORA2A | |
| SCHEMBL31210868 | 0.84 | ALDH1A1 (0.39) | ENPP1CCNE1CDK2ADORA2A | |
| SCHEMBL31210839 | 0.82 | SMPD3 (0.40) | SUV39H2USP30 | |
| SCHEMBL25105563 | 0.82 | SMPD3 (0.40) | SUV39H2USP30 | |
| SCHEMBL29267155 | 0.82 | USP30 (0.39) | ENPP1SUV39H2PARP1USP30CKS1B | |
| SCHEMBL25103828 | 0.82 | BCL6 (0.35) | ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |